IgA Nephropathy clinical trials at UCSF

1 research study open to eligible people

Showing trials for

  • Atrasentan in Patients With IgA Nephropathy

    open to eligible people ages 18 years and up

    The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

    San Francisco, California and other locations

Our lead scientists for IgA Nephropathy research studies include .

Last updated: